Advertisement
Australia markets open in 8 hours 20 minutes
  • ALL ORDS

    8,209.20
    -63.50 (-0.77%)
     
  • AUD/USD

    0.6685
    -0.0026 (-0.38%)
     
  • ASX 200

    7,971.60
    -64.90 (-0.81%)
     
  • OIL

    80.25
    -2.57 (-3.10%)
     
  • GOLD

    2,402.80
    -53.60 (-2.18%)
     
  • Bitcoin AUD

    100,807.34
    +1,077.73 (+1.08%)
     
  • CMC Crypto 200

    1,386.29
    +55.40 (+4.16%)
     

The Zacks Analyst Blog Highlights NextEra Energy, BP, Gilead Sciences, Hamilton Beach and FONAR

For Immediate Release

Chicago, IL – June 4, 2024 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: NextEra Energy, Inc. NEE, BP p.l.c. BP, Gilead Sciences, Inc. GILD, Hamilton Beach Brands Holding Co. HBB and FONAR Corp. FONR.

Here are highlights from Monday’s Analyst Blog:

Top Stock Reports for NextEra Energy, BP and Gilead Sciences

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including NextEra Energy, Inc., BP p.l.c. and Gilead Sciences, Inc., as well as two micro-cap stocks Hamilton Beach Brands Holding Co. and FONAR Corp.. The Zacks microcap research is unique as our research content on these small and under-the-radar companies is the only research of its type in the country.

These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

You can see all of today's research reports here >>>

NextEra Energy shares have outperformed the Zacks Utility - Electric Power industry over the past six months (+37.0% vs. +5.2%). The company continues to expand its operations through organic projects and acquisitions. The company will add more renewable projects in its portfolio and has nearly 21.5 GW of renewable projects in its backlog.

Efficient cost management is boosting the company's margins. Florida's improving economy boosts the company's subsidiary FPL's customer base. NextEra Energy is managing its debts efficiently and has ample liquidity to meet its debt obligations.

However, due to the nature of NextEra Energy's business, it is subject to complex rules and regulations. Risks in operating nuclear power-based generation units, unfavorable weather conditions, still-high interest rates and increasing supply costs can adversely impact earnings.

(You can read the full research report on NextEra Energy here >>>)

Shares of BP have gained +10.2% over the past year against the Zacks Oil and Gas - Integrated - International industry's gain of +15.5%. The company has a strong portfolio of upstream projects, supporting notable growth in production. The integrated energy company exhibits robust upstream growth with the start-up of major projects like Seagull, which boosts its production capacity.

Diversification into renewables through the Lightsource BP acquisition supports long-term sustainability amid energy transitions. The divestment strategy aims to reach $25 billion by 2025, enhancing the balance sheet and returning capital to shareholders.

However, a high debt-to-capitalization ratio raises financial flexibility and balance sheet concerns. Also, despite resolving significant litigation expenses from the 2010 oil spill, BP had to sell valuable assets. These divestitures could potentially limit future cash generation. Refining margins may face pressure due to narrower crude differentials.

(You can read the full research report on BP here >>>)

Gilead has underperformed the Zacks Medical - Biomedical and Genetics industry over the past year (-14.3% vs. -9.5%). The company's recent pipeline setbacks weigh on Gilead. Gaining incremental market share is likely to be a daunting task due to the competition in the HIV market and the saturated oncology space.

Nevertheless, Gilead's flagship HIV therapy, Biktarvy, continues to maintain its strong growth, thereby fueling the top line. The approval of new therapies has boosted its market-leading HIV franchise. Our estimates for Biktarvy indicate a CAGR of around 5.8% over the next three years, driven by continued market growth.

Substantial growth in Yescarta and Tecartus and the strong uptake of Trodelvy have strengthened its oncology franchise. The company's efforts to bolster its oncology and virology franchise through internal pipeline development and strategic collaborations are encouraging.

(You can read the full research report on Gilead Sciences here >>>)

Shares of Hamilton Beach have outperformed the Zacks Household Appliances industry over the past year (+104.2% vs. -23.2%). This microcap company with market capitalization of $270.90 million has diversified its product portfolio with a focus on innovation and energy efficiency, marketing well-known brands and expanding into health technology.

Financially, HBB has improved its position by reducing debt from $79.3 million to $50 million. The gross profit margin rose significantly to 23.4% in first-quarter 2024, driven by cost efficiencies and favorable product mixes. HBB's recent dividend increase to 11.5 cents per share demonstrates its commitment to shareholder value.

However, revenue growth remained unchanged year over year due to pricing pressures and competitive markets. Supply-chain risks, supplier concentration in China and a centralized distribution strategy expose HBB to operational disruptions. Selling and administrative expenses have risen primarily due to new ventures and higher employee costs.

(You can read the full research report on Hamilton Beach here >>>)

FONAR's have underperformed the Zacks Medical - Products industry over the past year (-9.8% vs. +3.5%). This microcap company with market capitalization of $98.66 million is witnessing rising SG&A expenses and decreased cash flow from operations signal potential operational challenges. Increased competition, reliance on HMCA and regulatory risks are key concerns.

Despite economic uncertainties and limited revenue diversification, FONAR's legacy in MRI technology and continued R&D investment provide a solid foundation for future growth. Inventory management issues and sector-specific vulnerabilities persist.

Nevertheless, FONAR has shown strong financial performance for the nine months ending Mar 31, 2024, with total revenues up 5.6% and net income rising 25.3%, reflecting effective cost management. Adoption of SwiftMR technology positions FONAR competitively. Strategic expansion, a robust balance sheet, and a diversified revenue stream strengthen its market position.

(You can read the full research report on FONAR here >>>)

ADVERTISEMENT

Since 2000, our top stock-picking strategies have blown away the S&P's +7.0 average gain per year. Amazingly, they soared with average gains of +44.9%, +48.4% and +55.2% per year.

Today you can access their live picks without cost or obligation.

See Stocks Free >>

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

support@zacks.com                       

https://www.zacks.com

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

NextEra Energy, Inc. (NEE) : Free Stock Analysis Report

BP p.l.c. (BP) : Free Stock Analysis Report

Gilead Sciences, Inc. (GILD) : Free Stock Analysis Report

Fonar Corporation (FONR): Free Stock Analysis Report

Hamilton Beach Brands Holding Company (HBB) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research